The implied probability of Kalshi’s valuation topping $40 billion in an IPO scenario rose to 28%, from 12%.
The figures concern a conditional valuation outcome if the company goes public; they do not establish Kalshi’s value or confirm IPO plans.
Investing
The probability was 12% earlier, according to the supplied figures.

The implied probability of Kalshi’s valuation topping $40 billion in an IPO scenario rose to 28%, from 12%.
The figures concern a conditional valuation outcome if the company goes public; they do not establish Kalshi’s value or confirm IPO plans.
The regulator cited manipulation risks in contracts tied to what people say. Kalshi said it is complying with the CFTC's order.
The Wall Street Journal reported the plan as an exclusive. ETF analyst Eric Balchunas also described the additions in an X post.
Kalshi's AppliedXL pilot covers late-stage trials and Food and Drug Administration decisions, with employment checks and listings after enrollment ends.